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Abstract
Background: Shigella spp. are one of the most common causes of paediatric dysentery globally, responsible for a
substantial proportion of diarrhoeal disease morbidity and mortality, particularly in industrialising regions. Alarming
levels of antimicrobial resistance are now reported in S. flexneri and S. sonnei, hampering treatment options. Little is
known, however, about the burden of infection and disease due to Shigella spp. in the community.
Methods/Design: In order to estimate the incidence of this bacterial infection in the community in Ho Chi Minh
City, Vietnam we have designed a longitudinal cohort to follow up approximately 700 children aged 12–60 months
for two years with active and passive surveillance for diarrhoeal disease. Children will be seen at 6 month intervals
for health checks where blood and stool samples will be collected. Families will also be contacted every two weeks
for information on presence of diarrhoea in the child. Upon report of a diarrhoeal disease episode, study nurses will
either travel to the family home to perform an evaluation or the family will attend a study hospital at a reduced
cost, where a stool sample will also be collected. Case report forms collected at this time will detail information
regarding disease history, risk factors and presence of disease in the household.
Outcomes will include (i) age-specific incidence of Shigella spp. and other agents of diarrhoeal disease in the
community, (ii) risk factors for identified aetiologies, (iii) rates of seroconversion to a host of gastrointestinal
pathogens in the first few years of life. Further work regarding the longitudinal immune response to a variety of
Shigella antigens, host genetics and candidate vaccine/diagnostic proteins will also be conducted.
Discussion: This is the largest longitudinal cohort with active surveillance designed specifically to investigate
Shigella infection and disease. The study is strengthened by the active surveillance component, which will likely
capture a substantial proportion of episodes not normally identified through passive or hospital-based surveillance. It is
hoped that information from this study will aid in the design and implementation of Shigella vaccine trials in the future.
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Background
Diarrhoea remains a major cause of childhood morbid-
ity and mortality globally [1,2], with the vast majority
of the 1.7 billion annual infections and 0.7 million
deaths occurring in low and middle-income countries
[3]. The four species of the Gram-negative bacterial
genus Shigella (S. flexneri, S. sonnei, S. boydii and S. dysen-
teriae) are amongst the most common causes of dysen-
teric diarrhoea worldwide, with >164 million infections
estimated annually in 1999 [4]. There is a growing neces-
sity to prevent and control Shigella infections due to a
dramatic emergence of highly resistant strains in not only
southeast Asia [5-7], but in many other countries in both
high and low income settings [8-16]. There are also exten-
sive knowledge gaps regarding the distribution, incidence
and exposure to Shigella spp., including a paucity of infor-
mation on age-specific incidence, which is essential for
assessing disease burden and evaluating the benefits of
any future vaccines.
To address the outstanding epidemiological questions
related to Shigella infections, we are conducting a longi-
tudinal cohort study focusing on diarrhoeal disease with
both routine and active surveillance components in Ho
Chi Minh City (HCMC) in southern Vietnam. HCMC is
a densely populated, rapidly urbanizing setting home to
over 7.5 million people with a per-capita annual income
of $1,220 [17]. The burden of Shigella infections is
known to be substantial in children in Vietnam [5,18]. A
previous cohort study conducted in the early 2000s in
the coastal province of Khanh Hoa in central Vietnam
estimated an incidence rate of 490/100,000/year in
children under the age of five years through passive
surveillance of diarrhoeal cases [19]. Although several
longitudinal, community-based cohorts in Southeast
Asia have been established within the last two decades
to investigate diarrhoeal disease, very few have included
an active disease surveillance component [19-24]. Active
surveillance is challenging for obvious reasons, including
the substantial cost, intensive staff and resource needs, dif-
ficulty in ascertainment and confusion on what is con-
sidered to be an ‘episode’ of diarrhoea by parents or
guardians.
The overall aim of this study is to describe the epi-
demiology of Shigella infections in HCMC to inform the
development and introduction of Shigella vaccines. The
primary objective of this study will be to define the age-
specific incidence and exposure of Shigella infection in
children ≤ 60 months of age in the community in HCMC.
Secondary objectives include (1) determination of the age-
specific incidence of other agents of diarrhoeal infection
in the community (2) a description of risk factors for both
Shigella as well as other diarrhoeal aetiologies (3) evalu-
ation of seroconversion rate (presence of antibody) to
diarrhoeal pathogens at six month intervals in the first five
years of life (4) exploration of the relationship between
maternal and infant IgG and protection against infection
and (5) an investigation into potential host genetic suscep-
tibilities for diarrhoeal disease.
Methods/Design
In order to achieve our objectives, we have designed a
longitudinal cohort study with routine and active sur-
veillance for diarrhoeal disease in district eight of HCHC
(Figure 1). This district is a densely populated district in
the center of the city with a large number of canals and
waterways and is known to contribute proportionally
more hospitalized pediatric shigellosis patients than any
of the other districts in the city [5].
Cohort population
Children enrolled into our cohort will be recruited from
an existing birth cohort conducted to investigate the in-
cidence of dengue and other viral infections across our
study site [24]. Briefly, pregnant mothers living in dis-
trict eight were enrolled prior to delivery at Hung Vuong
Hospital (HVH), a large obstetric hospital in HCMC de-
livering approximately 44,000 babies annually. Infants
were followed up routinely for the first 12 months of life
for the purposes of investigating the epidemiology, aeti-
ology and risk factors of a variety of viral infections in
infancy. Clinical samples were collected at routine visits
corresponding to Expanded Programme on Immunization
(EPI) visits at 0, 4, 9 and 12 months of age, including
throat and nasopharyngeal swabs as well as a small blood
sample. A subset of these children have been followed
beyond 12 months of age and are still undergoing rou-
tine follow up every six months.
Enrolment & routine follow up
Children who had been enrolled in the existing birth co-
hort will be approached for entry into the diarrhoeal dis-
ease cohort between 12–36 months of age at a routine
birth cohort follow up visit. An enrolment questionnaire
will be administered, detailing information on demo-
graphic and socioeconomic characteristics of the house-
hold, with a particular focus on water sources, water
treatment and toilet practices. Once enrolled, children
are requested to attend HVH every six months for a
routine health check, as shown in Figure 2. A blood
sample (<2 ml), a nasopharyngeal swab and an anal swab
or stool sample (if available) is collected by study nurses
at these routine visits. Additionally, a questionnaire re-
garding growth and disease episodes of the child in the
preceding six months will be administered. Routine fol-
low up will take place for a total of two years for each
child.
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Active & passive case detection
Parents/guardians will be contacted through a text mes-
sage or phone call on a regular basis to request informa-
tion on whether the enrolled child has had an episode of
diarrhoea in the preceding seven days. Diarrhoea is de-
fined according to the guidelines outlined by the World
Health Organization, which is three or more loose stools
in a 24 hour period or at least one bloody/mucoid stool
[25]. If the parent cannot be reached on the initial at-
tempt, the study nurse will make every effort to establish
contact to ensure complete data collection. Once a par-
ent alerts a study nurse to an episode of diarrhoea,
the nurse will travel to the participant’s home within
a 24-hour window. At the home visit, a stool sample
will be collected. If no fresh stool is available at the
time of the visit, a sterile stool collection pot will be
left with the parents/guardians with instructions for
sample collection. Stool pots left at the home will be
collected within 24 hours. Furthermore, a short case
report form (CRF) will be collected detailing clinical
details of the diarrhoeal episode and information on
any other known diarrhoeal infections in the house-
hold. The parents will also be given oral rehydration
packets, probiotics containing Lactobacillus acidoph-
ilus as well as zinc supplements for the child [26,27].
If at any point during follow up a parent feels that
their child requires medical attention for diarrhoeal dis-
ease and feels that a home visit by a nurse is insufficient,
they may attend the Hospital for Tropical Disease (HTD)
at a subsidised cost (Figure 2). Upon arrival at the hospital
the children will be escorted through registration pro-
cesses by a study nurse who will then lead them to the
gastrointestinal ward for clinical evaluation (both inpatient
and outpatients). A stool sample will be collected, and a
Figure 1 The location for the cohort study. Left panel: Location of Vietnam (dark grey) in Southeast Asia, with Ho Chi Minh City shown by the
red star. Right panel: A satellite map showing Ho Chi Minh City, with district 8 highlighted in red. The boundaries of other districts are shown in
black. Waterways are shown in blue.
Figure 2 Flowchart of study design. Children are enroled at age 12–36 months with routine follow up visits (shown in blue bars) every
6 months. During enrolment and routine follow up visits, a stool sample, blood sample and nasopharyngeal swab (NPS) will be collected in
addition to a case report form detailing growth and health information. Follow up will continue for a total of two years for each child, meaning
they will exit the cohort at 36–60 months of age. Parents will be contacted on a regular basis to enquire whether their child has experience
diarrhoeal disease. When the child experiences an episode of diarrhoea (shown in red bars), study nurses can travel to the home of the
participant to a stool sample and a short case report form or the family can bring the child to the Hospital for Tropical Disease for clinical
examination. Stool will be collected during diarrhoeal episodes.
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blood sample if clinically indicated. A detailed CRF will be
administered collecting clinical, laboratory and haemato-
logical information if available.
Clinical and laboratory investigations
All samples will be labeled with a study number to en-
sure anonymity and transported to the microbiology la-
boratory at the Oxford University Clinical Research Unit
(OUCRU) for analysis and storage on the same day as
collection. Samples from disease episodes will undergo
microscopy for blood cells and parasites (Giardia lamblia,
Entamoeba histolytica and Cryptosporidium) as well as
microbiology culture for Shigella spp., Salmonella spp.,
Campylobacter spp. and Escherichia coli. Antimicrobial
susceptibility testing of the cultured and identified bacter-
ial pathogens will be performed by the disc diffusion
method using the guidelines of the Clinical and Labora-
tory Standards Institute (CLSI) [28]. Results will be re-
ported back to the treating clinician as soon as they are
available.
Aliquots of stool from both healthy routine visits and
from disease episodes will be stored at −80°C. Total nu-
cleic acid will be extracted from faecal specimens using
the QIAamp viral RNA Mini kit (QIAGEN, Hilden,
Germany) or using the Roche MagNA pure 96 auto-
mated nucleic acid extraction machine (Roche). RNA
will be converted to complementary DNA (cDNA) by
reverse transcription (RT) and an aliquot of RNA will be
stored −80°C. For RT, extracted RNA will be reverse-
transcribed by SuperScript Reverse Transcriptase III and
RNAse Inhibitor (Invitrogen) combined with a random
hexamer (Roche Diagnostics, UK) according to manufac-
turer’s instructions. The resulting cDNA will be stored
at −80°C. Bacterial PCR will be performed on extracted
nucleic acids to potentially increase the diagnosis rate of
Shigella spp., Salmonella spp. and Campylobacter spp.
Viral pathogens will be identified through batch multi-
plex realtime PCR procedures to identify rotavirus and
norovirus [29]. Additionally, blood samples will be sepa-
rated into plasma for serology purposes and cells will be
stored for future host genetics studies. Specifically, ELI-
SAs will be used to measure IgA, IgM and IgG subtypes
to S. sonnei O-antigen to evaluate seroconversion
rates [30].
Sample size
We estimate that we will enroll between 650–750 chil-
dren based on the available population and current attri-
tion rates from the original birth cohort [24]. It is
known that the median age of hospitalized Shigella infec-
tions in HCMC is 24 months [5]. Additionally, the annual
incidence of diarrhoea in Vietnam in children under five
years of age is 1.5 events/child/year [19]. Therefore, we es-
timate that we will have 2,100 diarrhoeal episodes in our
cohort during two years of follow up. From a cohort study
in Hanoi, the Shigella positivity rate is approximately 6%
of passively detected diarrhoeal cases in children under
5 years [20]. Therefore, we conservatively estimate that we
will detect approximately 125 Shigella diarrheal episodes
over the study period through both passive and active sur-
veillance activities.
Data management
Each patient will have a unique identifying study code
such that sample and documents will not be labeled with
any identifying information. Data will be collected elec-
tronically whenever possible, including on laptops and
on handheld tablets provided to the study nurses and
hospital wards. Electronic data entry devices will be
password protected and accessible only by authorised
users. Paper CRFs will be used in the event of power
failure or technical difficulty. A central database has
been developed to ensure secure and confidential data
management.
Ethical approval & ethical considerations
Ethical approval for this study has been obtained from
the Oxford University Tropical Research Ethics Commit-
tee (OxTREC approval 1058–13) as well as from local
partners including the Institutional Review Board (IRB)
at the Hospital for Tropical Diseases (HTD) and the IRB
at Hung Vuong Hospital (HVH). Written informed con-
sent will be obtained from parents/guardians of children
at the time of enrolment for both participation as well as
storage and future use of pathogenic and human sam-
ples. Parents/guardians will be assured that all informa-
tion generated in this study will remain confidential.
Participant families are reimbursed for travel costs to
our study sites for routine or disease visits as well as
tests involved in the standard of care (full blood count,
stool microscopy and microbiology) of diarrhoeal disease
at HTD. Furthermore, parents/guardians are free to
withdraw their consent for their child at any time and
request that study samples not be stored for further
testing.
Discussion
In this work we have described a longitudinal cohort
designed to estimate the incidence of diarrhoea due to
Shigella in the community in HCMC, Vietnam. This
study will follow an estimated 650–750 children under
the age of five for two years each, collecting informa-
tion at routine follow up visits and during diarrhoeal
disease events through both passive and active surveil-
lance. We aim not only to estimate the incidence of
Shigella but also to examine the immune response and
risk factors for infection and disease.
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Study strengths
The burden of diarrhoeal disease is difficult to accur-
ately estimate [31], and hospitalized illness is generally
not representative of infection and disease in the com-
munity [32]. Therefore, the most important strength of
the study is the active surveillance component as we
will be able to estimate the true burden of diarrhoea
due not only to Shigella, but due to a variety of other
diarrheal aetiologies in the community as well. Longitu-
dinal blood samples will also provide for the ability to esti-
mate rates seroconversion to Shigella sonnei O-antigen
[33], which will capture potential Shigella infections that
we do not identify through our active and passive surveil-
lance. An additional strength of this study is the collabor-
ation with the existing birth cohort established at OUCRU
[24]. Such a partnership will allow for data and sample
sharing for all participants from birth through at least the
first three years of life, providing for the opportunity to
explore dynamics of infection and immunity from infancy.
Limitations
The major, predicted limitations of this study are loss to
follow up and incomplete diarrhoeal disease ascertain-
ment. Differential loss to follow up would introduce bias
into the results as participants who remain are likely dif-
ferent than those who were lost. Therefore, we will ensure
that the rapport between study nurses and participants re-
mains strong through continuous training and mainten-
ance of motivation of the nurses. We have made a
significant effort to provide the families with a high
level of comprehensive care for diarrhoeal disease in
hopes that they will value the overall research programme
and continue to participate through the follow up period.
Additionally, we are investing heavily in terms of time and
personnel to ensure that we capture as many diarrhoeal
disease episodes as possible through intensive active sur-
veillance and follow up.
Future work
The humoral immune response to Shigella is partly in-
duced by the O-antigen and is thought to be serotype
specific [34,35]. However, the immune response to the
O-antigen as well as other non-polysaccharide Shigella
antigens in children in endemic areas after symptomatic
infection or exposure is extremely ill-defined [36]. We
will explore the longitudinal immune response to a
range of Shigella antigens in infected individuals in an
endemic setting with a view of identifying novel vaccine
and diagnostic candidates and their serological relation-
ship to the O-antigen. To interrogate the diversity, spe-
cificity and longevity of the humoral immune response a
range of Shigella antigens, a Shigella antigen-array will
be constructed in collaboration with the Wellcome Trust
Sanger Institute. Similar approaches have been used for
development of other bacterial vaccines and diagnostics
such as Salmonella and Brucella melitensis [37,38].
Additionally, we hope to explore the relationship be-
tween genetic variation and disease susceptibility through
genetic association, candidate gene and genome wide as-
sociation studies in the future. Host DNA samples will be
stored and used for genotyping to investigate potential
genetic associations with diarrhoeal disease. Additionally,
the development of gastrointestinal and respiratory tract
flora will be measured by performing metagenomic ana-
lysis from the anal and nasopharyngeal swabs.
Conclusions
In conclusion, we have designed one of the largest longi-
tudinal, active surveillance cohort studies to study Shi-
gella infection and disease in children in Southeast
Asia. Through this study, we will be able to estimate
an incidence of Shigella infection and disease and de-
fine the epidemiology of the bacteria in this commu-
nity, which is representative of many densely crowded,
industrializing cities globally. We also hope to eventu-
ally more clearly define the longitudinal immune re-
sponse to this emergent, highly antimicrobial resistant
pathogen [12], as well as begin exploration into host
susceptibility to infection. Samples, data and analyses
from this work are hoped to be a valuable resource to
international as well as local medical and public health
communities for informing the development and de-
ployment of a Shigella vaccine in the future.
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